Earth Science Tech, Inc. (OTC: ETST), a diversified holding company focused on health and wellness, has announced the acquisition of Zoolzy LLC, a Florida-based wholesale distributor of active pharmaceutical ingredients (APIs) and finished FDA-approved prescription products. The move is expected to enhance ETST’s supply chain, reduce procurement costs, and open new revenue streams in the veterinary sector.
Zoolzy operates from a 3,684-square-foot facility in Doral, Florida, and will be integrated into ETST’s existing operations. By bringing Zoolzy in-house, ETST’s compounding pharmacies will gain direct access to APIs at competitive wholesale pricing, which the company says could increase overall profit margins. This vertical integration is a key part of ETST’s strategy to build a seamless healthcare platform that connects patient care from consultation to fulfillment.
The acquisition also provides ETST with immediate procurement access to common veterinary medications. The company plans to leverage this new supply line to expand into the animal health market, developing unique, flavored, and easy-to-administer veterinary therapeutics. This initiative will be led by members of ETST’s management team who have experience and established networks in the exotic wildlife space.
According to the press release, the acquisition aligns with ETST’s broader goal of becoming a vertically integrated healthcare provider. The company’s portfolio includes compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment, supported by investments in real estate and asset management. By adding Zoolzy, ETST aims to strengthen its supply chain and reduce dependence on third-party distributors, which could lead to better pricing and availability of medications.
The move into veterinary medicine represents a significant growth opportunity. The animal health market is expanding, with increasing demand for customized medications for pets and exotic animals. ETST’s focus on flavored and easy-to-administer therapeutics could differentiate its offerings in a niche segment. The company’s management’s experience in the exotic wildlife space may provide valuable insights into the needs of veterinarians and animal owners, potentially leading to innovative products.
Financial details of the acquisition were not disclosed. However, the strategic rationale is clear: by controlling more of its supply chain, ETST can improve margins and offer a wider range of products. The acquisition also diversifies ETST’s revenue streams, reducing reliance on any single market segment.
This development is noteworthy for investors and industry observers because it highlights the growing trend of consolidation and vertical integration in the pharmaceutical compounding industry. As regulatory pressures increase and competition intensifies, companies like ETST are seeking ways to cut costs and expand their service offerings. The acquisition of Zoolzy could serve as a model for other firms looking to enhance their competitive position.
For more information, the full press release is available at https://ibn.fm/nHFqQ, and updates on ETST can be found in its newsroom at https://ibn.fm/ETST.
